Product Description
Johnson & Johnson is developing Seltorexant as a treatment for major depressive disorder with insomnia symptoms. (Sourced from: https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx)
Mechanisms of Action: OX2R Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Germany, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 2: Alzheimer Disease|Insomnia
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 42847922MDD3003 | P3 |
Recruiting |
Depressive Disorder, Major |
2026-12-30 |
|
| CR109177 | P2 |
Completed |
Alzheimer Disease |
2023-11-10 |
32% |
| CR108810 | P3 |
Completed |
Depressive Disorder, Major |
2023-10-03 |
|
| CR109099 | P1 |
Completed |
Healthy Volunteers |
2023-05-12 |
28% |